<span item_type="fundamental" item_id="ed2d1d145ee5cf84f26f25fcafcbfa41" counter_id="ST/US/RAPH" env="prod"></span><span item_type="announcement" item_id="549080098005779585" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD 0.02.</p><p></p><h3>Segment Revenue</h3><p>Raphael Pharmaceutical Inc. did not generate any revenue during the three months and six months ended June 30, 2025, and June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></p><h3>Operational Metrics</h3><h4>Research and Development Expenses</h4><ul><li>Three months ended June 30, 2025: $141,000 (increase of $117,000 or 588% compared to $24,000 for the three months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li><li>Six months ended June 30, 2025: $213,000 (decrease of $190,000 or 47% compared to $403,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h4>General and Administrative Expenses</h4><ul><li>Three months ended June 30, 2025: $174,000 (decrease of $51,000 or 23% compared to $225,000 for the three months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li><li>Six months ended June 30, 2025: $527,000 (increase of $134,000 or 35% compared to $393,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h4>Operating Loss</h4><ul><li>Three months ended June 30, 2025: $315,000 (increase of $66,000 or 27% compared to $249,000 for the three months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li><li>Six months ended June 30, 2025: $740,000 (decrease of $56,000 or 7% compared to $796,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h4>Financial Expense, net</h4><ul><li>Three months ended June 30, 2025: $6,000 (increase of $7,000 or 700% compared to financial income, net of $1,000 for the three months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li><li>Six months ended June 30, 2025: $11,000 (increase of $9,000 or 550% compared to $2,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Three months ended June 30, 2025: $322,000 (increase of $74,000 or 30% compared to $248,000 for the three months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li><li>Six months ended June 30, 2025: $751,000 (decrease of $47,000 or 6% compared to $798,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h3>Cash Flow</h3><h4>Net Cash Used in Operating Activities</h4><ul><li>Six months ended June 30, 2025: - $239,000 (decrease of $151,000 compared to - $390,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h4>Net Cash Provided by Financing Activities</h4><ul><li>Six months ended June 30, 2025: $240,000 (decrease of $40,000 compared to $280,000 for the six months ended June 30, 2024).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><p>Raphael Pharmaceutical Inc. plans to continue investigating its lead product candidate for the treatment of rheumatoid arthritis and aims to develop a novel treatment for asthma. The company is leveraging insights from pre-clinical experiments conducted at Rambam Health Care Campus to advance its understanding of both COVID-19 and asthma symptoms.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></p><h4>Non-Core Business</h4><p>The company announced the completion of product development and the launch of its proprietary natural formula under the “RaphaWell” brand for RA support in the United States. This product will be sold as a standalone clinically tested dietary supplement targeting the growing wellness market.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></p><h4>Priority</h4><p>Raphael Pharmaceutical Inc. anticipates requiring approximately $700,000 for research and development activities and $500,000 for capital expenditures over the next 12 months. The company is focused on obtaining FDA approvals for its product candidates and intends to apply for European Medicines Agency and other countries’ governmental regulatory agencies approvals if necessary.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1415397/000121390025075662/ea0252567-10q_raphael.htm"></span></p>

Raphael Pharmaceutical Inc. | 10-Q: FY2025 Q2 EPS: USD 0.02